Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate versus tocilizumab for giant cell arteritis
2024-512269-14-00Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in giant cell arteritis (GCA) comparing Tocilizumab arm with Methotrexate arm (2 arms). Primary endpoint: Sustained remission without prednisone schedule deviation at week 78. Started Jan 2020; status: completed.
02
Drugs
tocilizumabmethotrexate
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2024-512269-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512269-14-00.